HC Wainwright Equities Analysts Boost Earnings Estimates for Biora Therapeutics, Inc. (NASDAQ:BIOR)

Biora Therapeutics, Inc. (NASDAQ:BIOR) – Research analysts at HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for Biora Therapeutics in a note issued to investors on Tuesday, April 9th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($1.92) for the year, up from their prior forecast of ($3.11). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Biora Therapeutics’ current full-year earnings is ($2.06) per share. HC Wainwright also issued estimates for Biora Therapeutics’ FY2025 earnings at ($1.61) EPS, FY2026 earnings at ($1.39) EPS, FY2027 earnings at ($1.35) EPS and FY2028 earnings at ($1.18) EPS.

Biora Therapeutics Price Performance

NASDAQ BIOR opened at $0.70 on Thursday. The business has a 50 day simple moving average of $1.00 and a 200 day simple moving average of $1.34. Biora Therapeutics has a one year low of $0.67 and a one year high of $6.70. The stock has a market capitalization of $21.37 million, a P/E ratio of -0.08 and a beta of 1.09.

Institutional Investors Weigh In On Biora Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp acquired a new stake in Biora Therapeutics in the third quarter valued at approximately $27,000. Virtu Financial LLC acquired a new stake in Biora Therapeutics in the fourth quarter valued at approximately $27,000. CIBC Asset Management Inc acquired a new stake in Biora Therapeutics in the first quarter valued at approximately $42,000. Commonwealth Equity Services LLC acquired a new stake in Biora Therapeutics in the third quarter valued at approximately $63,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in Biora Therapeutics in the first quarter valued at approximately $118,000. Institutional investors and hedge funds own 43.74% of the company’s stock.

Biora Therapeutics Company Profile

Biora Therapeutics, Inc, a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases.